Biogen

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.

CEO

Christopher A. Viehbacher

CEOChristopher A. Viehbacher

Employees

7,500

Employees7,500

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1978

Founded1978

Employees

7,500

Employees7,500

BIIB Key Statistics

Market cap

31.91B

Market cap31.91B

Price-Earnings ratio

23.19

Price-Earnings ratio23.19

Dividend yield

—

Dividend yield—

Average volume

1.42M

Average volume1.42M

High today

$219.00

High today$219.00

Low today

$209.01

Low today$209.01

Open price

$211.46

Open price$211.46

Volume

1.15M

Volume1.15M

52 Week high

$219.72

52 Week high$219.72

52 Week low

$121.05

52 Week low$121.05

Stock Snapshot

With a market cap of 31.91B, Biogen(BIIB) trades at $216.12. The stock has a price-to-earnings ratio of 23.19.

On 2026-07-04, Biogen(BIIB) stock traded between a low of $209.01 and a high of $219.00. Shares are currently priced at $216.12, which is +3.4% above the low and -1.3% below the high.

Biogen(BIIB) shares are trading with a volume of 1.15M, against a daily average of 1.42M.

In the last year, Biogen(BIIB) shares hit a 52-week high of $219.72 and a 52-week low of $121.05.

BIIB News

Simply Wall St 5h

Biogen Could Be 1% Undervalued Before Key AAIC Alzheimer’s Data

Advertisement Why Biogen’s AAIC 2026 data drop matters for the stock Biogen (BIIB) is in focus as it prepares to share detailed diranersen Phase 2 results and...

The Motley Fool 5h

Biogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors.

Biogen (BIIB +3.04%) built itself into a biotech giant thanks to its portfolio of multiple sclerosis (MS) drugs -- but in biotech and pharma, revenue growth dep...

Simply Wall St 2d

Biogen Stock Looks Near Fair Value After A 57% Run

Biogen stock has delivered a strong 57.5% return over the past year, yet the broader valuation checks suggest the shares now look closer to fairly priced than c...

Analyst ratings

58%

of 38 ratings

Buy

57.9%

Hold

36.8%

Sell

5.3%

More BIIB News

TipRanks 3d

Biogen says Q2 results to include $164M expense on a pre-tax basis

In a regulatory filing, the company stated, “Biogen (BIIB) expects that its GAAP and non-GAAP results for the second quarter of 2026 will include acquired in-pr...

Benzinga 5d

Biogen: Key Takeaways From Needham’s Meeting With Top Management

Spinraza HD uptake has been “quite positive,” with demand matching Spinraza’s launch levels, driven by both new and returning patients, Fadia wrote. She also ci...

Simply Wall St 6d

Biogen Is Up 9.9% After US$1 Billion RayThera Deal And Salanersen Win - Has The Bull Case Changed?

Earlier this week, Biogen drew attention as Axtria honored its transformation leaders at Axtria Ignite 2026, while the company also advanced its push beyond dec...

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.